The circulatory small non-coding RNA landscape in community-acquired pneumonia on intensive care unit admission

Community-acquired pneumonia (CAP) is a major cause of sepsis. Despite several clinical trials targeting components of the inflammatory response, no specific treatment other than antimicrobial therapy has been approved. This argued for a deeper understanding of sepsis immunopathology, in particular factors that can modulate the host response. Small non-coding RNA, for example, micro (mi)RNA, have been established as important modifiers of cellular phenotypes. Notably, miRNAs are not exclusive to the intracellular milieu but have also been detected extracellular in the circulation with functional consequences. Here, we sought to determine shifts in circulatory small RNA levels of critically ill patients with CAP-associated sepsis and to determine the influence of clinical severity and causal pathogens on small RNA levels. Blood plasma was collected from 13 critically ill patients with sepsis caused by CAP on intensive care unit admission and from 5 non-infectious control participants. Plasma small RNA-sequencing identified significantly altered levels of primarily mature miRNAs in CAP relative to controls. Pathways analysis of high or low abundance miRNA identified various over-represented cellular biological pathways. Analysis of small RNA levels against common clinical severity and inflammatory parameters indices showed direct and indirect correlations. Additionally, variance of plasma small RNA levels in CAP patients may be explained, at least in part, by differences in causal pathogens. Small nuclear RNA levels were specifically altered in CAP due to Influenza infection in contrast to Streptococcus pneumoniae infection. Pathway analysis of plasma miRNA signatures unique to Influenza or Streptococcus pneumoniae infections showed enrichment for specific proteoglycan, cell cycle, and immunometabolic pathways.     

In silico synteny based comparative genomics approach for identification and characterization of novel therapeutic targets in Chlamydophila pneumoniae

Chlamydophila pneumoniae is one of the most important and well studied gram negative bacterial strain with respect to community acquired pneumonia and other respiratory diseases like Chronic obstructive pulmonary disease (COPD), Chronic asthma, Alzheimer''s disease, Atherosclerosis and Multisclerosis which have a great potential to infect humans and many other mammals. According to WHO prediction, COPD is to become the third leading cause of death by 2030. Unfortunately, the molecular mechanisms leading to chronic infections are poorly understood and the difficulty in culturing C pneumoniae in experimental conditions and lack of entirely satisfactory serological methods for diagnosis is also a hurdle for drug discovery and development. We have performed an insilico synteny based comparative genomics analysis of C pneumoniae and other eight Chlamydial organisms to know the potential of C pneumoniae which cause COPD but other Chlamydial organisms lack in potential to cause COPD though some are involved in human pathogenesis. We have identified total 354 protein sequences as non-orthologous to other Chlamydial organisms, except hypothetical proteins 70 were found functional out of which 60 are non homologous to Homo sapiens proteome and among them 18 protein sequences are found to be essential for survival of the C pneumoniae based on BLASTP search against DEG database of essential genes. CELLO analysis results showed that about 80% proteins are found to be cytoplasmic, Among which 5 were found as bacterial exotoxins and 2 as bacterial endotoxins, remaining 11 proteins were found to be involved in DNA binding, RNA binding, catalytic activity, ATP binding, oxidoreductase activity, hydrolase activity and proteolysis activity. It is expected that our data will facilitate selection of C pneumoniae proteins for successful entry into drug design pipelines.     

重症肺炎新生儿支气管肺泡灌洗液 病原菌分布及耐药性

目的研究重症肺炎新生儿支气管肺泡灌洗液的病原菌分布和耐药性。方法选择2016年4月至2018年4月在本院呼吸科治疗的新生儿268例,其中符合重症肺炎诊断标准的患儿142例,归为重症肺炎组;不符合重症肺炎诊断标准的患儿126例,归为对照组。检测患儿肺泡灌洗液病原菌分布情况和耐药情况。结果重症肺炎组患儿肺炎克雷伯菌、流感嗜血菌、铜绿假单胞菌、阴沟肠杆菌、大肠埃希菌、金黄葡萄球菌、溶血葡萄球菌、表皮葡萄球菌、肺炎链球菌、草绿链球菌检出率明显高于对照组。肺炎克雷伯菌对亚胺培南,美罗培南的耐药性为0.0%,大肠埃希菌对亚胺培南,美罗培南,阿米卡星的耐药性为0.0%,阴沟肠杆菌对亚胺培南,美罗培南,左氧氟沙星的耐药性为0.0%,肺炎链球菌对万古霉素的耐药性为0.0%,金黄葡萄球菌对万古霉素的耐药性为0.0%。结论新生儿重症肺炎患者病原菌以革兰阴性菌为主,亚胺培南、美罗培南、万古霉素可以用于治疗新生儿重症肺炎,但由于其毒副作用较大,应严格把握适应症。     

Anti-inflammatory roles of mesenchymal stromal cells during acute Streptococcus pneumoniae pulmonary infection in mice

Background

Pneumonia is the fourth leading cause of death worldwide, and Streptococcus pneumoniae is the most commonly associated pathogen. Increasing evidence suggests that mesenchymal stromal cells (MSCs) have anti-inflammatory roles during innate immune responses such as sepsis. However, little is known about the effect of MSCs on pneumococcal pneumonia.

S. aureus Evades Macrophage Killing through NLRP3-Dependent Effects on Mitochondrial Trafficking

1. Download high-res image (228KB)
2. Download full-size image

     

Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease

Fibrotic interstitial lung diseases are illnesses of unknown cause characterized by progressive decline in lung function. Fibrocytes are bone marrow-derived, circulating progenitor cells capable of differentiating into diverse mesenchymal cell types. Prior work has shown fibrocytes to traffic to the lung via the CXCL12-CXCR4 chemokine axis in an animal model of pulmonary fibrosis. We therefore assessed the relevance of fibrocytes in patients with fibrotic interstitial lung disease. We found enhanced expression of CXCL12 in both the lungs and plasma of patients with lung fibrosis. CXCL12 levels were associated with an order of magnitude higher number of circulating fibrocytes in the peripheral blood of these patients. Most of the circulating fibrocytes in patients with interstitial lung diseases were negative for the myofibroblast marker alpha-smooth muscle actin, suggesting a relatively undifferentiated phenotype. Taken together, these data suggest that fibrocytes are involved in the pathogenesis of human lung fibrosis.     

血清FKN、APC与老年社区获得性肺炎患者病情和预后不良的关系

摘要 目的：探讨血清分形趋化因子（FKN）、活化蛋白C（APC）与老年社区获得性肺炎（CAP）患者病情和预后不良的关系。方法：选取2020年1月～2023年1月潍坊市人民医院收治的314例老年CAP患者为CAP组,根据病情程度分为低危组104例、中危组123例、高危组87例,根据入院30d生存状况分为死亡组65例和存活组249例,另选取同期100名体检健康老年人为对照组。采用酶联免疫吸附法检测血清FKN、APC水平。采用受试者工作特征（ROC）曲线分析血清FKN、APC水平对老年CAP患者预后不良的预测价值。通过多因素Logistic回归分析老年CAP患者预后不良的影响因素。结果：与对照组比较,CAP组血清FKN水平升高,APC水平降低（P＜0.05）。低危组、中危组、高危组老年CAP患者血清FKN水平依次升高,APC水平依次降低（P＜0.05）。多因素Logistic回归分析显示,病情高危、机械通气和C反应蛋白（CRP）、FKN升高为老年CAP患者预后不良的独立危险因素,APC升高为其独立保护因素（P＜0.05）。ROC曲线分析显示,FKN、APC水平单独和联合预测老年CAP患者预后不良的曲线下面积分别为0.783、0.789、0.870,二者联合对老年CAP患者预后不良的预测价值大于各指标单独预测。结论：血清FKN水平升高和APC水平降低参与着老年CAP患者病情进展,血清FKN联合APC能较好地预测老年CAP患者预后不良。     

小儿肺热咳喘颗粒联合雾化吸入用乙酰半胱氨酸溶液对支气管肺炎患儿肺通气功能、炎症因子和免疫球蛋白的影响

摘要 目的：观察小儿肺热咳喘颗粒联合雾化吸入用乙酰半胱氨酸溶液对支气管肺炎患儿肺通气功能、炎症因子和免疫球蛋白的影响。方法：选择2019年9月-2023年1月期间合肥市第二人民医院收治的100例支气管肺炎患儿,采用双色球法将患儿分为对照组和研究组,各为50例。对照组患儿接受雾化吸入用乙酰半胱氨酸溶液,研究组患儿在对照组的基础上接受小儿肺热咳喘颗粒。对比两组临床症状、炎症因子水平[白细胞介素-6（IL-6）、降钙素原（PCT）、C反应蛋白（CRP）]、免疫球蛋白[免疫球蛋白（Ig）A、IgM、IgG]、肺通气功能指标[吸气时间（TI）、呼气时间（TE）、吸呼比（TI/TE）、达峰时间比（TPF%TE）、达峰容积比（VPF%VE）]和不良反应发生率。结果：与对照组相比,研究组的肺部湿啰音消失时间、咳嗽消失时间、咳痰消失时间、退热时间更短（P<0.05）。研究组治疗10 d后CRP、IL-6、PCT低于对照组（P<0.05）。研究组治疗10 d后IgA、IgM、IgG高于对照组（P<0.05）。研究组治疗10 d后VT、TI、TE、TI/TE、TPF%TE、VPF%VE高于对照组（P<0.05）。两组不良反应发生率对比未见差异（P>0.05）。结论：小儿肺热咳喘颗粒联合雾化吸入用乙酰半胱氨酸溶液治疗支气管肺炎,可有效缩短临床症状缓解时间,改善肺通气功能,降低炎症因子水平,调节免疫球蛋白,且安全性较好。     

Low-dose whole thorax radiation therapy for COVID-19 pneumonia: inpatient onboarding process for a randomized controlled trial

BackgroundThe mortality of the SARS-CoV-2 virus (COVID-19) has been associated with a pulmonary inflammatory response resulting in hypoxemia and rapid clinical decline. PREVENT is an ongoing prospective multicenter Phase II randomized controlled trial where patients hospitalized with COVID-19 pneumonia are randomized to low dose radiation therapy (RT) versus control (clinicaltrials.gov, {"type":"clinical-trial","attrs":{"text":"NCT04466683","term_id":"NCT04466683"}}NCT04466683). We describe the inpatient onboarding process of the center contributing the largest number of patients to this trial.Materials and methodsCOVID-19 hospital admissions were attained by the clinical research manager and radiation oncologist daily. Text message contact was made with infectious disease, critical care, and nursing staff with reciprocal discussion of the trial protocol and approval for virtual consulting of the patient. Witnessed informed consent was obtained first by telephone and later in person. Simulation and treatment (performed without a computer plan) was performed on a linear accelerator with one personal protective equipment-protected therapist moving in and out of the treatment room, and a second therapist manning the console. Following on-site dose calculation by physics, the radiation oncologist approved the fields prior to treatment delivery.ResultsBetween August 28, 2020 and October 6, 2020, the first 10 enrolled patients on this multicenter trial were randomized and treated at our institution; no team member (research staff, radiation oncology) contracted COVID-19 while employing this protocol.ConclusionThis represents the first published protocol to address efficient and safe recruitment of COVID-19 patients for a radiation oncology trial, serving as a model for conducting recruitment of COVID-19 patients for clinical trials.